Organon & (OGN) Stock Price

Organon & Price

NYSE·CLOSED
13.90
​
Market closed

Revenue at Organon & has contracted by 6.3% per year over the past 8 years to 6.22 B USD. Earnings per share have declined at 24.2% per year over the last 8 years. Organon &'s net margin stands at 3.0%, down from 21.4% several years earlier. Organon & currently offers a dividend yield of about 2.45%. The payout ratio is around 47% of earnings. Analysts set a median price target of 12.00 USD, implying 13.7% below the current price. Of 13 analysts, 0 rate the stock a buy — an overall Sell consensus.

Organon & stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & business model & stock analysis

Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers.

Frequently asked questions about Organon &

Analysts currently set an average price target of 11.33 USD for the Organon & stock (median: 12.00 USD), implying -18.5 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Organon & stock: 0 recommend buying, 7 holding and 6 selling. For 2026, analysts expect Organon & to generate revenue of 6.16 B USD and earnings per share of 3.43 USD.

Converted at the current exchange rate, the Organon & share trades at 12.60 EUR (13.90 USD).

The Organon & share (OGN) is listed on 7 stock exchanges, including: NYSE (OGN), London (0A9W.L), XETRA (7XP.DE), Frankfurt (7XP.F), München (7XP.MU), Düsseldorf (7XP.DU).

The expected revenue of Organon & is 6.16 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Organon & is 893.32 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Organon & is currently 4.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Organon & stock.

The price-to-sales ratio (P/S) of Organon & is currently 0.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Organon & stock.

The Eulerpool Quality Score for Organon & is 2/10.

The ISIN of Organon & is US68622V1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Organon & is A3CPKP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Organon & is OGN. The ticker symbol is used to trade Organon & shares on the stock exchange.

Fair ValueTerminal
11.54 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
621,600.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website organon.com
Currency
USD
Initial public offering
May 14, 2021
ISIN
US68622V1061
Cusip
68622V106
Market capitalization
3.61 B USDMid Cap
52-Week Range
PEG
7.54
P/E ratio
P/Ee 2026
4.05
P/Ee 2027
3.81
P/Ee 2028
3.47
P/Ee 2029
3.66
P/Ee 2030
3.56
P/S
P/Se
0.59
EV/EBIT
9.21
P/B Ratio
4.81
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.96 %
Dividend
Dividend yield
2.45 %
Est. Dividend Yield
0.58 %
Payout Ratio
47.30 %
Dividend growth Ø5Y
—
Dividend payments per year
4
Dividend paid since
5 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Nov 16, 2026, 3:39 AM

Organon & Peer Group

Organon & Ticker

DÜSSELDORF · 7XP.DUFRANKFURT · 7XP.FLONDON · 0A9W.LMILAN · 1OGN.MIMUNICH · 7XP.MUNEW YORK · OGNXETRA · 7XP.DE

Organon & FIGI

OGN:US · BBG00ZQRGW24OGN:UA · BBG00ZQRJTX4OGN:UC · BBG00ZQRJTY3OGN:UN · BBG00ZQRJV05OGN:UP · BBG00ZQRJV14OGN:UB · BBG00ZQRJV41OGN:UT · BBG00ZQRJV50OGN:UM · BBG00ZQRJV69OGN:UX · BBG00ZQRJV78OGN:UD · BBG00ZQRJVD1OGN:UF · BBG00ZQRJVH7OGN:VY · BBG00ZQRJVJ5

All fundamentals and in-depth analysis of Organon &

Our stock analysis for Organon & stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Organon &. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.